Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562062 | 1.00 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL898388 | 1.00 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL15847150 | 0.89 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4MAPT | |
| SCHEMBL1081119 | 0.89 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4MAPT | |
| SCHEMBL6041975 | 0.89 | CA2 (0.49) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL29979605 | 0.88 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL879857 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL4294384 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL2724163 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL3490631 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 740 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0987264-A1 | 4,4-DIFLUORO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPINE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-03-22 | — | — | EP | claimed |
| US-4806655-A | Process for the stereospecific synthesis of indole derivatives | SOCIETE ANONYME: SANOFI (FR) | 1989-02-21 | — | — | US | claimed |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2026-04-23 | — | — | US | disclosed |
| US-20260097111-A1 | ETHER LIPIDS FOR HYPERACTIVATION OF MAMMALIAN DENDRITIC CELLS | CORNER THERAPEUTICS, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4218754-B1 | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4648753-B1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3634402-B1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-4665181-A | Anti-inflammatory phthalazinones | PENNWALT CORPORATION (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0212535-A1 | N6-disubstituted purine derivatives, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1987-03-04 | — | — | EP | disclosed |
| EP-0191448-A2 | Antihypertensive dihydropyridine derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| US-4595690-A | Hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4579861-A | Aryloxypropanolamine derivatives, pharmaceutical compositions and adrenegic thereof | PIERREL S.P.A. (IT) | 1986-04-01 | — | — | US | disclosed |
| EP-0164593-A1 | Anti-inflammatory phthalazinones | FISONS CORPORATION (US) | 1985-12-18 | — | — | EP | disclosed |
| EP-0157876-A1 | HERBICIDAL 1-ARYL-$g(D)?2 -1,2,4-TRIAZOLIN-5-ONES | FMC Corporation (US) | 1985-10-16 | — | — | EP | disclosed |
| WO-1985001637-A1 | HERBICIDAL 1-ARYL-DELTA2-1,2,4-TRIAZOLIN-5-ONES | FMC CORPORATION (US) | 1985-04-25 | — | — | WO | disclosed |
| US-4439425-A | IMMUNOLOGY | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | CA2 421/4885ALDH1A1 2977/4885NPSR1 2799/4885 |
| US-20260097111-A1 | ETHER LIPIDS FOR HYPERACTIVATION OF MAMMALIAN DENDRITIC CELLS | TLR7, INPP5D, PLCD1 | CA2 2544/4885ALDH1A1 4369/4885NPSR1 2412/4885 |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A3, SLC26A4 | CA2 895/4885ALDH1A1 2326/4885NPSR1 2766/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CA2 4674/4885ALDH1A1 641/4885NPSR1 4573/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | CA2 476/4885ALDH1A1 2378/4885NPSR1 1431/4885 |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | CFTR, ABCC2, ABCC8 | CA2 2804/4885ALDH1A1 1781/4885NPSR1 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.